A randomized double-blind placebo-controlled parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer s Disease (AD)

Brief description of study

The purpose of this study is to learn more about how CNP520 affects the body and how to better diagnose, monitor, and treat Alzheimer's Disease. Differences in DNA among people may explain why different people have different responses to the same drug, different risks of developing certain diseases, different disease progression, etc. Genetic research looks at how DNA relates to these differences. Genetic material and information can also be obtained from other substances in your biological samples, such as RNA, which is important in making proteins. Samples and data will be used to study scientific questions related to CNP520, or the risk for developing the symptoms of Alzheimer's disease or related diseases, or the development of drugs to treat people who are at risk for developing the symptoms of Alzheimer's disease or related diseases. The results of this study may be combined with results of other studies for pooled analysis and interpretation.

Clinical Study Identifier: s17-00718
ClinicalTrials.gov Identifier: NCT03131453
Principal Investigator: Martin Sadowski
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.